MRM Health has appointed Michel Detheux as Chairman of the Board of Directors, taking over from Werner Cautreels.
Detheux brings more than three decades of experience in innovation and value creation in life sciences and was previously founding CEO of iTeos Therapeutics. He subsequently spearheaded iTeos’ landmark $2bn strategic collaboration with GlaxoSmithKline for its lead clinical programme. Detheux currently serves as Chairman of the Board at Egle Therapeutics and as a board member at Vor Bio.
Detheux said: “MRM Health has established a unique position at the intersection of microbiome science, clinical excellence and industrial scalability. MH002 is a promising candidate with the potential to fundamentally transform the treatment of immune-mediated diseases in the gut. I look forward to working closely with the management team and the Board of Directors to help shape the next stage of the Company’s development.”
Sam Possemiers, CEO of MRM Health, commented: “MRM Health is entering a pivotal phase, with MH002 advancing into phase 2b clinical development and significant momentum across the business. The appointments of Michel significantly strengthens our Board. This Board has been assembled to support MRM Health as we advance MH002 through phase 2b, prepare for late-stage development and position the Company for its next key milestones.”